SDC2 (Syndecan 2)

Independent cohort studies further support these findings. In summary, this study underscores the potential of SDC2 as a promising target for early diagnosis and therapeutic intervention in GC, with implications for other malignancies.

The ERG scoring system offers a novel perspective for deconvoluting HCC heterogeneity. Our findings suggest that SPP1+ macrophages spatially reshape the TME, providing a theoretical basis for optimizing prognostic stratification and personalized immunotherapy.

For genes examined in at least two papers, we summarized the reported accuracy measurements by presenting the average, minimum, and maximum values for each CpG group. This scoping review identifies a profound lack in the reporting of the CpG sites analyzed for non-invasive detection of CRC, which poses a challenge for the comparison of findings across studies.

ROC-Plotter and drug-gene interaction analyses indicated associations with therapy response, with approved compounds targeting FN1 and VWF. Overall, these findings reveal proteomic signatures of minimally invasive plasma small-EVs as promising markers associated with diagnosis, molecular subtyping, disease progression, and guiding therapeutic strategies in obese breast cancer patients.

Combining fecal mSDC2 with serum CEA and CA72-4 increased sensitivity for CRC detection in this single-center study, at the cost of reduced specificity. Validation in larger, screening-intended cohorts with predefined thresholds is warranted.

Mechanistically, muscle EV biogenesis is regulated by a NOTCH-SDC2 pathway that declines with age but is reactivated by exercise. Together, these findings define a muscle-to-tumor communication axis with therapeutic potential.

P4, N=84, Henan Cancer Hospital; Henan Cancer Hospital | Initiation date: Aug 2025 --> Apr 2026

The simplified multitarget stool test utilizing age-dependent cut-off values demonstrated promising performance for CRC screening across age groups in the Chinese population.

By integrating genetic, epigenetic, and inflammatory biomarkers, the FIT-sDNA-CA system effectively filters out confounding signals from intestinal inflammation, overcoming the low specificity limitation of traditional fecal DNA testing. As a highly accurate non-invasive triage tool, this system facilitates early risk stratification for patients with high-risk colorectal cancer symptoms and significantly reduces unnecessary endoscopic referrals.

mIHC analysis indicated reduced Th1 but increased Th2 and Th17 biomarkers in MSI-H CRC. This study identified key genes and immune microenvironment alterations regulated by hsa-miR-99a in CRC, offering novel insights and potential therapeutic targets for CRC treatment.

Applied to plasma samples from patients with various tumors (including colorectal, lung, breast, cervical, liver, and gastric cancers), the technology significantly improved the detection rates up to 100% of tumor-specific methylation biomarkers, such as SDC2, SHOX2, RASSF1A, ZNF671, Septin9, and BMP3. Therefore, this study provides an efficient, universal and user-friendly enrichment and accurate detection of mDNA, laying a methodological foundation for early cancer screening and prognosis assessment.

This study defines a novel molecular subtype for COAD, linking PCD dysregulation to distinct TME remodeling and therapeutic outcomes. Targeting the MDK-SDC2 axis with agents such as sunitinib may offer a promising strategy to overcome stromal-mediated immunotherapy resistance in the most lethal PCDS3 tumors.